20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT
Ref.: C.L.5.2020
The World Health Organization (WHO) presents its compliments to Member States and
has the honour to inform them that WHO has recently updated the national estimates for
Hepatitis B surface antigens (HBsAg) biomarker prevalence in children under five years of age
and the overall population. Prior to releasing these estimates, WHO is requesting that they be
reviewed by national authorities and encourages Member States to provide comments on the data
sources and estimates and share any information to improve their accuracy.
HBsAg carrier is a precondition for Hepatitis B Virus (HBV) associated with chronic
conditions such as liver cancer and cirrhosis. As the impact of HBV vaccination on liver cancer
and cirrhosis is difficult to measure the Secretariat based its estimates on pre- and
post-vaccination data from published studies documenting HBsAg prevalence in your region and
used a statistical model to generate country specific estimates.
Data were extracted on demographics of sample and geographical location via a systematic
review on HBsAg prevalence over the period January 1965 to October 2018. In addition, Gross
Domestic Product (GDP) per capita was assigned for each country using the UN database and
vaccinated cohorts were identified for each country by linking with WHO/UNICEF data on HBV
vaccine introduction (HBV third dose and birth dose). Member States are invited to nominate a
focal point by sending an email to
[email protected] by 28 February 2020 in order to email the
specific country estimates.
To predict the pre- and post-vaccination HBsAg prevalence by country WHO used a
statistical model presented during the Strategic Advisory Groups of Experts (SAGE) meeting of
18 to 20 October 2016. A logistical regression model with geospatial random effects was
developed including geographic and GDP difference in a distance matrix as part of a correlated
autoregressive function. Variables included were sex, age, bias (e.g. indigenous peoples),
vaccinated cohorts and the birth dose. Bayasian statistical package WINBUGS was used while a
validation on 10% of the sample was performed. More details of the statistical model are
available in the Hepatitis B surface antigen prevalence dashboard
http://whohbsagdashboard.com/#global-strategies.
WHO hopes that these estimates provide useful information to national programmes and
partner agencies when making policy decisions on Hepatitis B control strategies including HBV
vaccines and other disease reduction strategies. In addition, WHO believes these estimates can
be used to estimate the impact of vaccination, once the vaccine is introduced.
Page 2
C.L.5.2020
In the past, all estimates have benefited greatly from the interaction with Member States.
Therefore, WHO would be grateful to receive any additional data that would improve the
accuracy of these estimates on the data included up to date. Any serosurvey up to
December 2019 is eligible and will be screened according to the systematic review inclusion and
exclusion criteria. Inputs can be sent prior to 19 March 2020 by sending an email to Ms Ximena
Riveros, Department of Immunization, Vaccines and Biologicals, Family, Women’s and
Children’s Health (
[email protected]).
The World Health Organization takes this opportunity to renew to Member States the
assurance if its highest consideration.
GENEVA, 19 February 2020
Saatja: <
[email protected]>
Saadetud: 20.02.2020 11:14
Koopia: <
[email protected]>
Teema: WHO: C.L.5.2020 (HBsAg estimates)
Manused: C.L.5.2020 (HBsAg national estimates).pdf; C.L.5.2020 Arabic.pdf; C.L.5.2020
Chinese.pdf; C.L.5.2020 French.pdf; C.L.5.2020 Russian.pdf; C.L.5.2020 Spanish.pdf
Dear Member States of the World Health Organization,
Please find attached, in the six official languages, C.L.5.2020 regarding the national estimates
for Hepatitis B surface antigens biomarker prevalence.
Should you have questions regarding C.L.5.2020 please send an email to
[email protected].
Best regards,
Department of Governing Bodies
World Health Organization